JP2023521147A5 - - Google Patents

Info

Publication number
JP2023521147A5
JP2023521147A5 JP2022561637A JP2022561637A JP2023521147A5 JP 2023521147 A5 JP2023521147 A5 JP 2023521147A5 JP 2022561637 A JP2022561637 A JP 2022561637A JP 2022561637 A JP2022561637 A JP 2022561637A JP 2023521147 A5 JP2023521147 A5 JP 2023521147A5
Authority
JP
Japan
Prior art keywords
chimeric polypeptide
domain
polypeptide according
cell
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022561637A
Other languages
English (en)
Japanese (ja)
Other versions
JP7863331B2 (ja
JP2023521147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/026430 external-priority patent/WO2021207526A1/en
Publication of JP2023521147A publication Critical patent/JP2023521147A/ja
Publication of JP2023521147A5 publication Critical patent/JP2023521147A5/ja
Application granted granted Critical
Publication of JP7863331B2 publication Critical patent/JP7863331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022561637A 2020-04-09 2021-04-08 ヒンジドメインを有するヒト化notch受容体 Active JP7863331B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063007807P 2020-04-09 2020-04-09
US63/007,807 2020-04-09
US202163165588P 2021-03-24 2021-03-24
US63/165,588 2021-03-24
PCT/US2021/026430 WO2021207526A1 (en) 2020-04-09 2021-04-08 Humanized notch receptors with hinge domain

Publications (3)

Publication Number Publication Date
JP2023521147A JP2023521147A (ja) 2023-05-23
JP2023521147A5 true JP2023521147A5 (enExample) 2024-04-17
JP7863331B2 JP7863331B2 (ja) 2026-05-21

Family

ID=78023652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561637A Active JP7863331B2 (ja) 2020-04-09 2021-04-08 ヒンジドメインを有するヒト化notch受容体

Country Status (10)

Country Link
US (1) US12662675B2 (enExample)
EP (1) EP4132659A4 (enExample)
JP (1) JP7863331B2 (enExample)
KR (1) KR20220166833A (enExample)
CN (1) CN115666726A (enExample)
AU (1) AU2021251212A1 (enExample)
BR (1) BR112022020415A2 (enExample)
CA (1) CA3179954A1 (enExample)
IL (1) IL297092A (enExample)
WO (1) WO2021207526A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
EP4680748A1 (en) 2023-03-13 2026-01-21 Arsenal Biosciences, Inc. Synthetic pathway activators
EP4701654A2 (en) * 2023-04-25 2026-03-04 Arsenal Biosciences, Inc. Novel receptors for transcription regulation
WO2026055533A1 (en) * 2024-09-06 2026-03-12 The Regents Of The University Of California Synthetic receptors for engineered ligands

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333167B1 (en) * 2000-03-10 2001-12-25 American Home Products Corp. Methods and reagents for identifying inhibitors of proteolysis of membrane-associated proteins
CN103502466A (zh) * 2010-09-07 2014-01-08 斯隆-凯特林纪念癌症中心 用于γ-分泌酶测定的方法和组合物
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3262166A4 (en) * 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
CN115094062A (zh) 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
CA3034093A1 (en) * 2016-08-23 2018-03-01 The Regents Of The University Of California Proteolytically cleavable chimeric polypeptides and methods of use thereof
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス,インコーポレイティド キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法
KR102742741B1 (ko) 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
GB201818816D0 (en) 2018-11-19 2019-01-02 Synpromics Ltd Regulatory nucleic acid sequences
CA3120014A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Liver-specific viral promoters and methods of using the same
WO2021061791A1 (en) 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
US20220372101A1 (en) 2019-09-24 2022-11-24 The Regents Of The University Of California Novel receptors having a heterologous stop transfer sequence for ligand-dependent transcriptional regulation
US20220340637A1 (en) 2019-09-24 2022-10-27 The Regents Of The University Of California Notch receptors with minimal linker
WO2021061862A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with hinge domain
CN114728174A (zh) 2019-09-24 2022-07-08 加利福尼亚大学董事会 具有异源跨膜结构域的受体
AU2021256845A1 (en) 2020-04-14 2022-11-24 Eidgenössische Technische Hochschule Zürich Cell classifier circuits and methods of use thereof
WO2022117686A1 (en) 2020-12-01 2022-06-09 ETH Zürich Dna constructs comprising alternative promoters
WO2022140159A1 (en) 2020-12-24 2022-06-30 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors

Similar Documents

Publication Publication Date Title
JP2024500847A5 (enExample)
JP2021502104A5 (enExample)
JP2023085527A5 (enExample)
RU2355705C2 (ru) Одноцепочечное цикличное триспецифическое антитело
JP2024155943A5 (enExample)
FI4034252T3 (fi) Saranadomeenin sisältäviä Notch-reseptoreita
JP2021519072A5 (enExample)
JP2021529516A5 (enExample)
JP2024069352A5 (enExample)
JP2024023228A5 (enExample)
JP2020516276A5 (enExample)
JP2019531697A5 (enExample)
JP2023507729A5 (enExample)
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
JP2022548796A5 (enExample)
JP2022516964A5 (enExample)
JP2021512614A5 (enExample)
Zhu et al. Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F (ab′) 2 for efficient lysis of p185HER2 overexpressing tumor cells
AU2014225788A1 (en) Engager cells for immunotherapy
JP2023546725A5 (enExample)
RU2019126655A (ru) Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
JP2023532807A5 (enExample)
JP2014088414A5 (enExample)
JP2024525727A5 (enExample)
JP2021525537A5 (enExample)